Skip to main content
. 2020 Dec 28;24(1):101996. doi: 10.1016/j.isci.2020.101996

Figure 7.

Figure 7

The anticancer activity of 17-DMAG is partly dependent on KDM4B

(A) Western blot shows KDM4B expression in Rh30 wildtype (Rh30-WT) and KDM4B knockout (Rh30-KDM4B KO) cells.

(B) Rh30-WT and Rh30-KDM4B KO cells are treated with 100nM of 17-DMAG or 500nM of 17-AAG for 5 days, followed by crystal violet staining.

(C) The intensity of cells stained by crystal violet in Figure 7B is quantified by ImageJ, which is then normalized to the DMSO control.

(D) Rh30 cells are treated with 2.5μM of GSK-J4 for 5 days, followed by crystal violet staining. The values indicate the intensity of cells stained by crystal violet quantified by ImageJ, which is normalized to the DMSO control.

(E) The whole cell lysates of Rh30 cells treated with GSK-J4 for 72 hr are assessed by Western blot with indicated antibodies.

(F) Rh30 cells are treated with different concentrations of KDM5-C70 for 5 days, followed by crystal violet staining. The values indicate the intensity of cells stained by crystal violet quantified by ImageJ, which is normalized to the DMSO control.

(G) The whole cell lysates of Rh30 cells treated with KDM5-C70 for 72 hr are assessed by Western blot with indicated antibodies.